DelveInsight Blog
Related Article
![pharma-news-for-alnylam-bms-daichii-sankyo-vertex pharma-news-for-alnylam-bms-daichii-sankyo-vertex](https://assets.delveinsight.com/blog/wp-content/uploads/2024/06/25155241/pharma-news-for-alnylam-bms-daichii-sankyo-vertex.png)
Alnylam’s HELIOS-B Phase III Study of Vutrisiran; Bristol Myers Squibb Secures FDA Nod for KRAZATI and Cetuximab; Daichii Sankyo’s EZHARMIA® Receives Japan Approval; Vertex’s Phase I/II VX-880 Trial; argenx’s VYVGART Hytrulo FDA Approval
Alnylam's HELIOS-B Phase III Study of Vutrisiran Shows Positive Results, Meeting All Primary and Secondary Endpoints Alnylam Pharmaceuticals, Inc. reported encouraging topline outcomes from its HELIOS-B Phase III study of vutrisiran, an experimental RNAi therapy being developed to treat ATTR amyloidosis with car...
Find More![pharma-news-for-takeda-astrazeneca-johnson-and-johnson-bms pharma-news-for-takeda-astrazeneca-johnson-and-johnson-bms](https://assets.delveinsight.com/blog/wp-content/uploads/2024/06/18150914/pharma-news-for-takeda-astrazeneca-johnson-and-johnson-bms.png)
Takeda Showcase Phase III Results for Soticlestat; Imfinzi and Chemotherapy Combination Gains US Approval; Nipocalimab Shows Notable Efficacy in Phase II Study; Bristol Myers Squibb’s Augtyro FDA Approval; AstraZeneca’s Farxiga FDA Approval
Takeda Reveals Phase III Results for Soticlestat (TAK-935) in Dravet and Lennox-Gastaut Syndromes Takeda revealed topline results from its SKYLINE and SKYWAY studies. SKYLINE (TAK-935-3001) was a multicenter, randomized, double-blind Phase III trial assessing soticlestat (TAK-935) plus standard care against plac...
Find More![pharma-news-for-moderna-almirall-lilly-ipsen pharma-news-for-moderna-almirall-lilly-ipsen](https://assets.delveinsight.com/blog/wp-content/uploads/2024/06/11141344/pharma-news-for-moderna-almirall-lilly-ipsen.png)
Moderna’s Phase III Trials for Dual Influenza and COVID-19 Vaccine; Almirall’s Klisyri FDA Approval; Lilly’s Tirzepatide MASH Trial; Cycle Pharmaceuticals Acquisition of Vanda Pharmaceuticals; Ipsen’s Iqirvo FDA Approval
Moderna Reports Successful Phase III Trials for Dual Influenza and COVID-19 Vaccine Moderna, Inc. has reported that its Phase III trial for mRNA-1083, an experimental combination vaccine targeting both influenza and COVID-19, achieved its main objectives by generating a stronger immune response than the approved...
Find MoreEditor's Pick
Newsletter/Whitepaper
Recent Article
ASCO Conference 2024
![ASCO 2023 ASCO 2023](https://assets.delveinsight.com/img/events/american-society-of-clinical-oncology-conference-2024.png)
Live Coverage of ASCO 2024 Visit Now for Real-Time Insights and Analytical, Impactful Updates!